85 FR 143 pgs. 44894-44895 - Notice of Meeting

Next Article Next

Type: NOTICEVolume: 85Number: 143Pages: 44894 - 44895

FR document: [FR Doc. 2020–16030 Filed 7–23–20; 8:45 am]

Agency: Health and Human Services Department

Sub Agency: Agency for Healthcare Research and Quality

Official PDF Version: PDF Version

Pages: 44894, 44895

[top]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Notice of Meeting

AGENCY:

Agency for Healthcare Research and Quality, HHS.

ACTION:

Notice.

SUMMARY:

The Agency for Healthcare Research and Quality (AHRQ) announces a Special Emphasis Panel (SEP) meeting on "COVID-19 REVISION SUPPLEMENT APPLICATION ZHS1 HSR-0 (03) HEALTHCARE SYSTEMS & VALUE RESEARCH (HSVR)." This SEP meeting will be closed to the public.

DATES:

August 7, 2020.

ADDRESSES:

Agency for Healthcare Research and Quality, (Video Assisted Review), 5600 Fishers Lane, Rockville, Maryland 20850.

FOR FURTHER INFORMATION CONTACT:

Jenny Griffith, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, Agency for Healthcare Research and Quality, (AHRQ), 5600 Fishers Lane, Rockville, Maryland 20850, Telephone: (301) 427-1557.

SUPPLEMENTARY INFORMATION:

A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by the AHRQ, and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularly-scheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise.

[top] The SEP meeting referenced above will be closed to the public in accordance with the provisions set forth in 5 U.S.C. App. 2, section 10(d), 5 U.S.C. 552b(c)(4), and 5 U.S.C. 552b(c)(6). Grant applications for the "COVID-19 REVISION SUPPLEMENT APPLICATION ZHS1 HSR-0 (03) HEALTHCARE SYSTEMS & VALUE

RESEARCH (HSVR)" are to be reviewed and discussed at this meeting. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: July 20, 2020.

Virginia L. Mackay-Smith,

Associate Director.

[FR Doc. 2020-16030 Filed 7-23-20; 8:45 am]

BILLING CODE 4160-90-P